Tauopathies
Information
- Disease name
- Tauopathies
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05522387 | Active, not recruiting | Phase 2 | An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease | February 21, 2023 | September 30, 2024 |
| NCT05344989 | Active, not recruiting | Phase 1 | A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants | May 6, 2022 | July 2024 |
| NCT02676843 | Completed | Phase 2 | Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations | April 2016 | November 25, 2018 |
| NCT02860338 | Completed | COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE | January 2009 | December 2015 | |
| NCT03538522 | Completed | Phase 2 | A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 | September 15, 2018 | October 30, 2019 |
| NCT03938870 | Completed | CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease | August 18, 2015 | July 6, 2023 | |
| NCT04445831 | Completed | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease | July 31, 2019 | September 5, 2023 |
| NCT05080777 | Completed | N/A | Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems | September 28, 2021 | June 5, 2023 |
| NCT05202223 | Completed | N/A | Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers | January 15, 2022 | December 8, 2022 |
| NCT02103894 | Completed | Phase 1 | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects | February 2014 | September 2016 |
| NCT05527288 | Completed | N/A | A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population | January 28, 2021 | September 12, 2021 |
| NCT02294851 | Completed | Phase 1 | A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects | December 31, 2014 | April 30, 2016 |
| NCT06303921 | Recruiting | Early Phase 1 | Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503 | February 16, 2024 | February 2029 |
| NCT05318976 | Recruiting | Phase 2 | A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation | February 28, 2022 | December 31, 2024 |
| NCT05427448 | Recruiting | N/A | Validation of Blood Biomarkers for Alzheimer's Disease | November 24, 2022 | December 31, 2024 |
| NCT05508789 | Recruiting | Phase 3 | A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) | October 10, 2022 | April 30, 2027 |
| NCT06032026 | Recruiting | Early Phase 1 | Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15 | August 2, 2023 | July 31, 2028 |
| NCT06083467 | Recruiting | Early Phase 1 | CW2IP2: Imaging and Diagnostic Assessments | July 20, 2023 | July 31, 2028 |
| NCT01696591 | Unknown status | The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD | March 2012 | September 2013 | |
| NCT05321498 | Withdrawn | Phase 2 | Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation | June 2023 | October 26, 2023 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D024801